Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miocamycin
- Development stage
- Unknown
- Lead developer
- Meiji Seika Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Miocamycin is a macrolide antibiotic used primarily for the treatment of respiratory tract infections and other bacterial infections. It acts by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, thereby preventing peptide chain elongation. Miocamycin is structurally related to other macrolides such as erythromycin and josamycin. It has been developed and marketed mainly in Japan and some European countries for indications including pharyngitis, tonsillitis, bronchitis, pneumonia, and skin infections caused by susceptible organisms. The drug is generally well tolerated with a safety profile similar to other macrolides.
- Brand names
- Miocamycin
- Other names
- MiocamicinaMiokamycinMidecamycin acetateJosacine
02
Targets
Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on miocamycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miocamycin.